Synopsis:
Shares surged nearly 5% after the board announced a 10:1 bonus and 1:10 stock split. Strong revenue and profit growth, robust manufacturing capacity, export-sourcing success, and plans for an Agro-Pharma research lab highlight growth potential and strategic expansion.
The shares of the pharmaceutical company hit 5 percent upper circuit in today’s trading session after the company has fixed the record date for the purposes of a bonus & stock split in the ratio of 10:1 & 1:10, respectively.
With a market capitalization of Rs 78.42 crore, the shares of Welcure Drugs & Pharmaceuticals Ltd were trading at Rs 6.97 per share, increasing around 4.97 percent as compared to the previous closing price of Rs 6.64 apiece.
Bonus & Stock split
The shares of Welcure Drugs & Pharmaceuticals Ltd have seen bullish movement after the board of the company fixed Thursday, October 16, 2025, as the record date for the purposes stock split in the ratio of 1:10,i.e, Sub-division of 1 Equity share of face value of Rs. 10 each fully paid-up to 10 Equity shares of face value of Rs. 1 each fully paid-up.
Additionally, it announced a bonus issue in the ratio of 10:1, which means an Issue of 1 Bonus Share for every 10 Equity Shares held by the Equity Shareholders of the Company.
Also read: 4117% Net Profit Growth: Penny stock skyrockets 16% after reporting robust Q2 results
Financial & operational Highlights
Looking forward to the company’s financial performance, revenue increased by 1100 percent from Rs 21 crore in Q4FY25 to Rs 300 crore in Q1FY26. Further, during the same time frame, net profit increased by 667 percent from Rs 3 crore to Rs 23 crore.
Welcure Remedies excels in manufacturing various healthcare products, showcasing impressive production capabilities. The company produces over 2 lakh tablets, 40,000 oral suspensions, and 65,000 general dry injections per shift. In addition, they make over 40,000 cefa injections, 50,000 ampoules, 50,000 liquid injections, and 20,000 ophthalmic drops per shift, demonstrating strong capacity and a wide product range.
The company demonstrated strong export-sourcing capabilities, completing seven assignments worth Rs 299.91 crore by August 2025, earning a 5% commission with zero inventory or logistics risk, maintaining a debt-free model. Notable orders include Rs 42.8 crore each from Giant Exim and Ravina International, and a Rs 517 crore global mandate from Fortune Sagar Impex, generating Rs 25.85 crore service income in FY26.
Recently, the company plans to establish an Agro-Pharma Research Laboratory to convert agricultural and botanical inputs into pharma-grade products targeting public health. Estimated at Rs 70–80 crore, the project will be funded via a Qualified Institutional Placement (QIP) of up to Rs 80 crore, reflecting a strategic move into high-value, research-driven healthcare solutions.
Welcure Drugs & Pharmaceuticals operates in the pharma industry, but its business activities were closed during the year due to financial constraints. The company’s philosophy focuses on enhancing investor confidence through corporate practices based on conscience, openness, fairness, and professionalism.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
